Key result
Metastatic prostate cancer is linked to ~35% higher circulating triglycerides alongside elevated atherogenic markers.
Why the study?
Prostate cancer cells rely on lipids for growth, prompting the hypothesis that cardiovascular-targeted hyperlipidemic factors are dysregulated in metastatic disease.
Case-Control (n=105)
No
Metastatic prostate cancer is characterized by significantly elevated levels of triglycerides, ANGPTL3, Apo CIII, and leptin compared to localized prostate cancer and cancer-free controls, suggesting whole-body lipid metabolic rewiring that could potentially be targeted with existing lipid-lowering therapies.
Answers are grounded in this paper and cite their sources.
Should not yet change lipid management in prostate cancer; hypothesis-generating for targeted interventions in prospective trials.
Background/Objectives: Prostate cancer (PCa) cells are known to heavily depend on lipids to support their growth. We hypothesized that hyperlipidemic factors, for which inhibitors are already available and used to treat cardiovascular disease, would be dysregulated in metastatic PCa (mPCa). The goal of this case-control study, including 35 men per group, was to compare the levels of PCSK9, ANGPTL3, Apo CIII, leptin, and the lipid profile in patients with mPCa versus localized Gleason 8/9 PCa (lPCa) and patients at risk of developing PCa (controls). Methods: Protein levels were assessed using ELISAs, while lipids were measured using the Roche Cobas analytical platform. Results: The following circulating analytes were higher in mPCa: triglycerides (in mmol/L; controls 1.7 ± 1.2, lPCa 1.5 ± 0.7, mPCa 2.3 ± 1.2, p = 0.0004), Apo CIII (in µg/mL; control 110.7 ± 55.7, lPCa 115.0 ± 57.64, mPCa 159.9 ± 96.7, p = 0.0179), ANGPTL3 (in ng/mL; controls 41.7 ± 20.0, lPCa 42.8 ± 24.1, mPCa 57.3 ± 26.9, p = 0.0390), and leptin (in ng/mL, controls 9.6 ± 9.1, lPCa 8.2 ± 7.9, mPCa 17.7 ± 17.8, p < 0.0001). Surprisingly, PCSK9 levels were negatively correlated with LDL in the entire cohort. Conclusions: In this cohort of men, whole-body lipid metabolic rewiring is a feature restricted to the metastatic phase of prostate cancer, suggesting it may play a significant role in the progression toward more aggressive cancer forms. Given the availability of drugs targeting ANGPTL3 and Apo CIII, the therapeutic potential of these drugs should be evaluated in metastatic PCa.
No takes yet. Share an insight, caveat, or question.
Boulay et al. (2026) conducted a case-control in Metastatic prostate cancer and localized Gleason 8/9 prostate cancer (n=105). Metastatic prostate cancer (vs localized PCa and controls) vs. Localized Gleason 8/9 prostate cancer (n=35) and cancer-free men at risk of prostate cancer (n=35) was evaluated on Circulating triglyceride levels (mmol/L) (p=0.0004). Metastatic prostate cancer was associated with elevated triglycerides, ANGPTL3, Apo CIII, and leptin compared to controls.
Synapse has enriched 10 related papers. Consider them for comparative context: